SCHEMBL20600975

SCHEMBL20600975

Cc1ncccc1OC(=O)N1CCC(C(CC(C)C)NC(=O)c2ccc(F)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.43
IDO1 P14902 4/20 0.40
KCNH2 Q12809 2/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
PLD2 O14939 1/20 0.39
PLD1 Q13393 1/20 0.39
CCR1 P32246 3/20 0.39
KDM1A O60341 1/20 0.39
RAB9A P51151 1/20 0.38
GRIN2B Q13224 1/20 0.38
NOS2 P35228 1/20 0.38
HTR1A P08908 1/20 0.38
HTR7 P34969 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALDH1A1 P00352 2/20 0.37
BLM P54132 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20601136 0.92 IDO1 (0.49) GPR119IDO1KCNH2CCR1CYP3A4
SCHEMBL20600950 0.92 IDO1 (0.49) GPR119IDO1KCNH2CCR1CYP3A4
SCHEMBL20600885 0.92 IDO1 (0.41) IDO1KCNH2PLD2PLD1CCR1
SCHEMBL20600948 0.91 IDO1 (0.40) GPR119IDO1KCNH2MAPTTSHR
SCHEMBL20615642 0.90 IDO1 (0.49) IDO1KCNH2CCR1KDM1AGRIN2B
SCHEMBL20601058 0.90 IDO1 (0.41) IDO1KCNH2MAPTTSHRCCR1
SCHEMBL20601051 0.90 IDO1 (0.49) IDO1KCNH2CCR1KDM1AGRIN2B
SCHEMBL20600998 0.87 IDO1 (0.42) IDO1KCNH2MAPTTSHRCCR1
SCHEMBL20601069 0.86 IDO1 (0.42) IDO1KCNH2MAPTTSHRCCR1
SCHEMBL20601089 0.85 CCR1 (0.40) IDO1KCNH2MAPTTSHRPLD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10927078-B2 Modulators of indoleamine 2,3-dioxygenase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-02-23 US disclosed
US-10927078-B2 Modulators of indoleamine 2,3-dioxygenase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-02-23 US disclosed
US-20200165201-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-05-28 US disclosed
US-20200165201-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-05-28 US disclosed
EP-3645520-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-05-06 EP disclosed
CN-110709391-A Modulators of indoleamine2, 3-dioxygenase 葛兰素史克知识产权开发有限公司 2020-01-17 CN disclosed
WO-2019003141-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-03 WO disclosed
WO-2019003141-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200165201-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, TPH1 GPR119 41/4885IDO1 1/4885KCNH2 4106/4885
US-10927078-B2 Modulators of indoleamine 2,3-dioxygenase IDO1, IDO2, TPH1 GPR119 41/4885IDO1 1/4885KCNH2 4106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.